While all eyes in the biopharmaceutical world are currently trained on Bristol-Myers Squibb’s proposal to buy Celgene for $74 billion, it wasn’t that long ago that another company’s gaze was fixed on the Summit, NJ, drug maker.
In the early 2000s, before the FDA approved Celgene’s flagship multiple myeloma drug lenalidomide (Revlimid), Novartis (NYSE: NVS considered buying the company. It passed, unwilling to risk billions on an unapproved drug. Those details came from biopharma dealmaker George Golumbeski, who was profiled in Xconomy this week. Golumbeski rose through the ranks to top positions at both companies, eventually earning a reputation for… Read more »
UNDERWRITERS AND PARTNERS
Categories: AstraZeneca, BioNtech, Biotech, Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Bristol-myers Squibb, cancer, cancer immunotherapy, Celgene, China, Colorectal Cancer, CRISPR, Deals, Deerfield Management, Detroit blog main, Detroit top stories, dupilumab, Eli Lilly, Gene editing, Harvard University, Health Insurance, Indiana blog main, Indiana top stories, Industry, investing, IPO, Johnson & Johnson, Life Sciences, Merck, Multiple Sclerosis, National, National blog main, National top stories, New York blog main, New York top stories, Non-Small Cell Lung Cancer, Novartis, Principia Biopharma, Raleigh-Durham blog main, Raleigh-Durham top stories, Regeneron Pharmaceuticals, Roche, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Sanofi, Seattle blog main, Seattle top stories, startups, Texas blog main, Texas top stories, Voyager Therapeutics, Wisconsin blog main, Wisconsin top stories